{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:42Z","timestamp":1793771982126,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.leukres.2026.108179","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:29:23Z","timestamp":1770049763000},"page":"108179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1452-039X","authenticated-orcid":false,"given":"Akihiro","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-8629","authenticated-orcid":false,"given":"Abdulrahim Mohammed","family":"Basendwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-8540","authenticated-orcid":false,"given":"Henri","family":"Fero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-1369","authenticated-orcid":false,"given":"Fahad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108179_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108179_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108179_bib4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2026.108179_bib6","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.leukres.2026.108179_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-025-02194-w","article-title":"The role of CPX-351 in the acute myeloid leukemia treatment landscape: mechanism of action, efficacy, and safety","author":"Pagano","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2026.108179_bib8","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108179_bib9","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib10","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2026.108179_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108179_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108179_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib15","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108179_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-023-00948-x","article-title":"Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study","volume":"13","author":"Wang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108179_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.leukres.2026.108179_bib20","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib21","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108179_bib22","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108179_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.leukres.2026.108179_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106904","article-title":"Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA\/venetoclax","volume":"119","author":"Chojecki","year":"2022","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2026.108179_bib25","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108179_bib26","doi-asserted-by":"crossref","first-page":"E196","DOI":"10.1002\/ajh.26157","article-title":"Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)","volume":"96","author":"Salhotra","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib27","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162784","article-title":"Patients with TP53-mutated acute myeloid leukemia receiving intensive induction therapy have superior outcomes due to a higher rate of salvage therapy: a single institution, retrospective study","volume":"16","author":"Sumransub","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2026.108179_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108179_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2021-145947","article-title":"Comparing outcomes between liposomal daunorubicin\/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia","volume":"138","author":"Grenet","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib31","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2019-130379","article-title":"Hypomethylating agent and venetoclax combination yields comparable outcomes to CPX-351 in newly diagnosed acute myeloid leukemia","volume":"134","author":"Asghari","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/ajh.27694","article-title":"A phase II trial of geriatric assessment-guided selection of treatment intensity in older adults with AML","volume":"100","author":"Bhatt","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2206694","article-title":"Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis","volume":"28","author":"Sutter","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2026.108179_bib34","doi-asserted-by":"crossref","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received Venetoclax + Azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.leukres.2026.108179_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-025-04047-4","article-title":"Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1\/2 study and global phase 3 study","author":"Hosono","year":"2025","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108179_bib36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1186\/s12885-024-13000-3","article-title":"Efficacy and safety of venetoclax combination therapy for relapsed\/refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"24","author":"Jiao","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2026.108179_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2025.2604566","article-title":"Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment","author":"Oka","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2026.108179_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1700916","article-title":"Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors","volume":"20","author":"Carlo-Stella","year":"1997","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2026.108179_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/mutage\/gey014","article-title":"Chemotherapy-induced genotoxic damage to bone marrow cells: long-term implications","volume":"33","author":"May","year":"2018","journal-title":"Mutagenesis"},{"key":"10.1016\/j.leukres.2026.108179_bib42","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/59.suppl_4.S4","article-title":"Chemotherapy-associated hematopoietic toxicity","volume":"59","author":"Kuhn","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.leukres.2026.108179_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108179_bib44","unstructured":"National Comprehensive Cancer Network, Acute Myeloid Leukemia (Version 3.2026), 2026. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf\u3009 (accessed January 7, 2026)."},{"key":"10.1016\/j.leukres.2026.108179_bib45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106727","article-title":"A concise review on the molecular genetics of acute myeloid leukemia","volume":"111","author":"Padmakumar","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2026.108179_bib47","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.14823","article-title":"Acute myeloid leukaemia genomics","volume":"179","author":"Medinger","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108179_bib48","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","article-title":"Toward individualized therapy in acute myeloid leukemia: a contemporary review","volume":"1","author":"Kadia","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib49","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib50","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib51","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib52","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a southwest oncology group study","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2024-200413","article-title":"AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal phase 3 AML trial","volume":"144","author":"Shimony","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108179_bib54","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2026.108179_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J. Intern Med"},{"key":"10.1016\/j.leukres.2026.108179_bib56","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2026.108179_bib57","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108179_bib58","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:37:16Z","timestamp":1772872636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"alternative-id":["S0145212626000238"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108179","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108179"}}